טוען...
Hepatitis B reactivation during or after direct acting antiviral therapy – implication for susceptible individuals
INTRODUCTION: The FDA issued a warning following 24 cases of HBV reactivation during DAA therapy for HCV, including individuals with inactive, occult and past HBV infection. Clinical presentations ranged from asymptomatic fluctuations in HBV DNA to fulminant hepatic failure, liver transplantation an...
שמור ב:
| הוצא לאור ב: | Expert Opin Drug Saf |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5589072/ https://ncbi.nlm.nih.gov/pubmed/28471314 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14740338.2017.1325869 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|